CeriBell, Inc. (NASDAQ:CBLL) Director Sells $131,255.35 in Stock

CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) Director Rebecca B. Robertson sold 7,445 shares of the business's stock in a transaction dated Tuesday, June 17th. The shares were sold at an average price of $17.63, for a total value of $131,255.35. Following the completion of the transaction, the director now owns 21,230 shares in the company, valued at $374,284.90. This trade represents a 25.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

CeriBell Price Performance

NASDAQ:CBLL traded up $0.01 during trading hours on Friday, hitting $17.81. The company's stock had a trading volume of 72,212 shares, compared to its average volume of 281,151. CeriBell, Inc. has a 52-week low of $10.01 and a 52-week high of $32.75. The business's 50-day moving average is $16.61 and its two-hundred day moving average is $20.83. The company has a current ratio of 17.36, a quick ratio of 16.81 and a debt-to-equity ratio of 0.11.

CeriBell (NASDAQ:CBLL - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.43) by $0.07. The company had revenue of $20.49 million during the quarter, compared to analysts' expectations of $19.30 million. As a group, research analysts forecast that CeriBell, Inc. will post -2.46 EPS for the current fiscal year.

Institutional Investors Weigh In On CeriBell

A number of hedge funds and other institutional investors have recently modified their holdings of CBLL. FMR LLC purchased a new position in CeriBell during the 4th quarter valued at about $128,120,000. TPG GP A LLC acquired a new position in CeriBell in the 4th quarter valued at about $102,677,000. Red Tree Management LLC purchased a new position in CeriBell in the 4th quarter valued at about $57,083,000. Yu Fan acquired a new stake in shares of CeriBell during the 4th quarter worth about $31,631,000. Finally, ABG WTT Global Life Science Capital Partners GP Ltd purchased a new stake in shares of CeriBell during the fourth quarter worth about $28,160,000.

Wall Street Analyst Weigh In

CBLL has been the topic of a number of analyst reports. LADENBURG THALM/SH SH began coverage on shares of CeriBell in a research report on Friday, April 4th. They issued a "buy" rating and a $32.00 price objective on the stock. Canaccord Genuity Group reiterated a "buy" rating and set a $33.00 price target on shares of CeriBell in a research note on Wednesday, February 26th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $32.50.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.